Forbes -
31 Mar 2021 13:30

The stock price of Fate Therapeutics, a biopharmaceuticals company focused on oncology and immunology treatments based on natural killer T-Cell programs, has seen a large 20% drop in just five trading sessions. The decline is driven in part by the broader sell-off in high growth stocks...
Share this Article
Comment on this Article
Please to comment